38 results
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:21pm
of safety issues. The Company intends to explore the viability of developing CT2000 as a topical agent for the relief of eye pain. A potential advantage … of drug-related skin reactions. The primary endpoint of the dose escalation trail will be safety and tolerability of the slower dose titration
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:15pm
of safety issues. The Company intends to explore the viability of developing CT2000 as a topical agent for the relief of eye pain. A potential advantage … of drug-related skin reactions. The primary endpoint of the dose escalation trail will be safety and tolerability of the slower dose titration
10-Q
2024 Q1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
) are limited in their effectiveness and/or limited in the duration that they may be prescribed because of safety issues. The Company intends to explore … trail will be safety and tolerability of the slower dose titration; however, we will also be measuring blood concentrations of CC8464, which
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
target selectivity and a favorable in vitro cardiac safety profile (in vitro electrophysiology experiments where we measured differences between cells … study investigating safety, tolerability and pharmacokinetics of single and multiple ascending doses of CC8464 in healthy volunteers has been completed
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:45pm
target selectivity and a favorable in vitro cardiac safety profile (in vitro electrophysiology experiments where we measured differences between cells … study investigating safety, tolerability and pharmacokinetics of single and multiple ascending doses of CC8464 in healthy volunteers has been completed
10-K
1gula3qq0hiy0l5eafo
16 Apr 24
Annual report
4:48pm
8-K
EX-99.1
wusnn
9 Apr 24
Chromocell Issues Letter to Stockholders from Chief Executive Officer
8:30am
8-K
EX-99.1
m0l k7tbja
13 Mar 24
Regulation FD Disclosure
8:00am
8-K
EX-1.1
s8wl5hgncmz
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
8-K
EX-3.2
vkd3p
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
424B4
2c0b3b2x
20 Feb 24
Prospectus supplement with pricing info
5:30pm
424B4
bj2upcmbmrel
20 Feb 24
Prospectus supplement with pricing info
5:28pm
FWP
3btlm0iyzkzxvv2i38t
12 Feb 24
Free writing prospectus
8:09am
FWP
8vhc644t
6 Feb 24
Free writing prospectus
8:43pm
FWP
8zp 2tq2q4uujj6pxfot
31 Jan 24
Free writing prospectus
4:16pm